These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15651749)

  • 1. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
    Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
    Raison CL; Woolwine BJ; Demetrashvili MF; Borisov AS; Weinreib R; Staab JP; Zajecka JM; Bruno CJ; Henderson MA; Reinus JF; Evans DL; Asnis GM; Miller AH
    Aliment Pharmacol Ther; 2007 May; 25(10):1163-74. PubMed ID: 17451562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
    Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
    Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
    J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
    Klein MB; Cooper C; Brouillette MJ; Sheehan NL; Benkelfat C; Annable L; Weston F; Kraus D; Singer J;
    Contemp Clin Trials; 2008 Jul; 29(4):617-30. PubMed ID: 18262853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFNalpha-associated mood disorders.
    Schaefer M; Winterer J; Sarkar R; Uebelhack R; Franke L; Heinz A; Friebe A
    Psychosomatics; 2008; 49(5):442-6. PubMed ID: 18794514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of depression and somatic symptoms in patients on interferon alpha/ribavirin for chronic hepatitis C.
    Shakoor A; Shafqat F; Mehmud Te; Akram M; Riaz S; Iqbal Z; Khan AA
    J Ayub Med Coll Abbottabad; 2010; 22(4):6-9. PubMed ID: 22455250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
    Hauser P; Khosla J; Aurora H; Laurin J; Kling MA; Hill J; Gulati M; Thornton AJ; Schultz RL; Valentine AD; Meyers CA; Howell CD
    Mol Psychiatry; 2002; 7(9):942-7. PubMed ID: 12399946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser.
    Kalyoncu OA; Tan D; Mirsal H; Pektas O; Beyazyurek M
    J Psychopharmacol; 2005 Jan; 19(1):102-5. PubMed ID: 15671136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.
    Hauser P
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S35-50. PubMed ID: 15081102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
    Schaefer M; Schwaiger M; Garkisch AS; Pich M; Hinzpeter A; Uebelhack R; Heinz A; van Boemmel F; Berg T
    J Hepatol; 2005 Jun; 42(6):793-8. PubMed ID: 15885349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.